Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 04, 2015 10:35 AM ET

Life Sciences Tools and Services

Company Overview of Crown Bioscience, Inc.

Company Overview

Crown Bioscience, Inc., a preclinical CRO, provides drug discovery and development services to biotech and pharmaceutical partners focusing on oncology and metabolic disease therapeutic areas. The company’s proprietary HuPrime, HuKemia, HuBase, HuMark, HuTrial, and HuSignature platforms enable lead optimization and translational strategies to deliver clinical candidates. It offers oncology services, such as oncology databases, Ex vivo services, human surrogate trials, in vitro and in vivo services, preclinical formulations, translational research, and drug discovery services; and metabolic disease services, including in vivo and in vitro services, cardiovascular and metabolic disease (CVMD) ...

3375 Scott Boulevard

Suite 108

Santa Clara, CA 95054

United States

Founded in 2006

Phone:

855-827-6968

Fax:

888-882-4881

Key Executives for Crown Bioscience, Inc.

Co-Founder and Chief Executive Officer
Age: 51
Executive Chairman
Chief Financial Officer
Age: 50
Senior Vice President of Operation and General Manager of Crownbio Taicang Facility
Compensation as of Fiscal Year 2015.

Crown Bioscience, Inc. Key Developments

Crown Bioscience, Inc. Expands Life Science Product Offering with Recombinant Cell Lines

Crown Bioscience, Inc. announced that is has added cell lines for biological studies and oncology drug screening to their Life Science division’s catalog. Three new categories of cell lines are available for purchase: EML4-ALK Kinase-Live cell lines are Crown’s stable Ba/F3 clones expressing exogenous EML4-ALK fusion variants, including wild type and L1196M, F1174L and C1156Y mutations. They are ideal for cell-based screening of potential ALK inhibitors that can overcome Crizotinib resistance. PD-1 and PD-L1 recombinant cell lines are HEK 293T cells stably expressing exogenous human PD-1 or PD-L1. They are recommended for PD-1 or PD-L1 inhibitor or antibody drug screening. Pathway Reporter cell lines that can be used to study the activation or inhibition of key intracellular signaling pathways involved in cancer and other diseases. The Wnt Pathway Reporter cell line is the first of these to be released. This cell line contains a stably integrated Wnt reporter expression cassette with the firefly luciferase gene. The Wnt reporter expression is robustly induced by exogenous Wnt stimulation, which can be easily measured by the luciferase activity. This cell line is intended for screening of inhibitors or activators of Wnt signaling pathway, which is frequently activated abnormally in many human cancers. The release of these cell lines, in combination with the company’s recently launched in vivo grade isotype controls, and diabetic and cancer tissue samples from relevant models, enhances Crown Bioscience’s mission to provide 'gold standard' services and tools to clients within preclinical drug discovery, and ultimately help reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic.

Crown Bioscience, Inc. Presents at China Healthcare Investment Conference - Shanghai, Apr-01-2015 02:00 PM

Crown Bioscience, Inc. Presents at China Healthcare Investment Conference - Shanghai, Apr-01-2015 02:00 PM. Venue: Shangri-La Pudong Hotel, 33 Fu Cheng Road, Pudong, Shanghai 200120, China. Speakers: Guo-Liang Yu, Executive Chairman.

Crown Bioscience, Inc. Announces Partnership Agreement with National Resource Center for Mutant Mice

Crown Bioscience, Inc., has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice (NRCMM) and its commercial branch Nanjing Biotech Innovation Corporation (NBIC), in Nanjing, Jiangsu Province, China. The newly expanded strategic partnership will focus on the development of new immune-oncology experimental cancer models, along with other models, including diabetes and inflammation diseases, to advance immune-oncology translational research and the treatment of cancers and other diseases. Immune-oncology therapy has recently become an area of intense cancer pharmaceutical research, particularly with the recent regulatory approval of PD-1 antibody for the treatment of cancer.

Similar Private Companies By Industry

Company Name Region
Centerstone Research Institute Inc. United States
New England Biolabs, Inc. United States
Medpace Holdings, Inc. United States
BIOCON, Inc. United States
Acoustic Cytometry Systems, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
February 12, 2015
Molecular Response, LLC, PDX Business Unit
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Crown Bioscience, Inc., please visit www.crownbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.